Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3
monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol
suppression in patients with oestrogen receptor positive early breast cancer.